

# TUMOR & LIQUID BIOPSY (COMPARISON CHART)

Whether through solid tumor analysis or minimally invasive liquid biopsy, our approach delivers precise, actionable insights that help clinicians tailor treatment strategies and monitor disease progression effectively.

TESTS	GENES COVERED	SAMPLE TYPE	TURN AROUND TIME	BEST FOR	DOCTOR'S ORDER NEEDED?	MAIN BENEFIT
<b>Hotspot Panel</b>	50 genes	Tumor tissue (FFPE)	~10 days	Confirmed tumor diagnosis	Yes	Finds important tumor mutations
<b>Liquid Biopsy (Colon)</b>	15 genes	Blood (cfDNA)	~10 days	Advanced, recurrent, or metastatic colon cancer	Yes	Looks for tumor mutations for colon
<b>Liquid Biopsy (Breast)</b>	27 genes	Blood (cfDNA)	~10 days	Advanced, recurrent, or metastatic breast cancer	Yes	Looks for tumor mutations for breast
<b>Liquid Biopsy (Lung)</b>	28 genes	Blood (cfDNA)	~10 days	Advanced, recurrent, or metastatic lung cancer	Yes	Looks for tumor mutations for lung
<b>TruSight 500 (Tissue)</b>	523 DNA + 55 RNA genes	Tumor tissue (FFPE)	5-6 weeks	Immunotherapy, trials	Yes	Very detailed tumor DNA + RNA profile
<b>TruSight 500 (Blood)</b>	523 genes	Blood (cfDNA)	5-6 weeks	Advanced tumors, no biopsy possible	Yes	Minimally invasive, real-time monitoring
<b>GTx-200</b>	200 genes	Tumor tissue (FFPE)	5-6 weeks	All Solid Tumors	Yes	Customizable panel up to 200 genes
<b>GTx-500 Plus</b>	Over 500 genes	Tumor tissue (FFPE)	5-6 weeks	All Solid Tumors	Yes	Customizable panel up to 500 plus genes